An experimental monoclonal antibody called ianalumab had promising results for more than half of patients with primary immune thrombocytopenia enrolled in a phase 3 trial, according to data published ...
The addition of ianalumab to eltrombopag significantly improved outcomes for patients with pretreated primary immune ...
Patients with immune thrombocytopenia (ITP) who received a first-in-class investigational drug in addition to standard ...
Clinical Trials Arena on MSN
Novartis reports positive data from VAYHIT2 trial for immune thrombocytopenia
Novartis has reported positive outcomes from the VAYHIT2 Phase III trial assessing ianalumab plus eltrombopag to treat ...
A recent study reveals thrombocytopenia as a significant prognostic factor in low-risk MDS, impacting survival and treatment ...
Ianalumab (9 mg/kg) plus eltrombopag extended ITP disease control by 45% with patients maintaining disease control 2.8 times longer than with placebo plus eltrombopag1,262% of patients treated with ...
More than half of patients in a Phase III clinical trial who received a limited course of the experimental monoclonal antibody ianalumab for primary immune thrombocytopenia were able to maintain safe ...
New phase 3 data showed that patients with primary immune thrombocytopenia saw improved disease control when ianalumab was ...
Depakote is a medication that contains divalproex sodium. It can treat seizures, mania, and migraine headaches. Thrombocytopenia is a potential side effect. The molecule divalproex sodium breaks down ...
Please provide your email address to receive an email when new articles are posted on . A 65-year-old male presented for his annual exam. The medical assistant (MA) checking the patient in remarked ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback